555 Mission Street, Suite 3000, San Francisco, CA 94105-0921 USA
Ryan Murr is a partner in the San Francisco office of Gibson, Dunn & Crutcher, where he serves as a member of the firm’s Corporate Transactions Department, with a practice focused on representing leading companies and investors in the life sciences and technology space. Mr. Murr currently serves as a Co-Chair of the firm’s Life Sciences Practice Group and previously served as a member of the firm’s Executive Committee and Management Committee.
Mr. Murr represents public and private companies and investors in the biotechnology, pharmaceutical, technology, medical device and diagnostics industries in connection with securities offerings and business combination transactions. In addition, Mr. Murr regularly serves as principal outside counsel for publicly traded companies and private venture-backed companies, advising management teams and boards of directors on corporate law matters, SEC reporting, corporate governance, licensing transactions, and mergers & acquisitions.
Recognized by Chambers USA in the area of Life Sciences, clients describe Mr. Murr as “creative and smart” and someone who “gets the better of the other side.”
Legal Media Group (Euromoney) has ranked Mr. Murr nationally as a “Star” in Life Sciences in the areas of Corporate, Licensing & Collaboration, Mergers & Acquisitions and Venture Capital. Mr. Murr has twice been nominated by Legal Media Group as “Finance & Transactional Attorney of the Year.”
Mr. Murr has served as a member of the American Bar Association’s Mergers and Acquisitions Subcommittee and is active in advising various not-for-profit entities in the San Francisco Bay Area.
Mr. Murr regularly represents issuers in a range of capital markets transactions, including initial public offerings, private placements (ranging from early-stage investments to crossover rounds and PIPEs), follow-on equity financings and debt financings. Mr. Murr has deep experience with a range of financing transaction structures beyond traditional underwritten offerings, including at-the-market offerings, rights offerings, PIPEs, and equity lines. Over the past decade, Mr. Murr has filed over 70 registration statements with the U.S. Securities and Exchange Commission, registering securities for offerings by issuers in the life sciences industry.
Mr. Murr also regularly represents investors in the life sciences and technology space, including private equity funds, hedge funds, and venture capital funds. Financing transactions have included public and private offerings ranging from passive investments to bespoke control structures and spin-outs.
Mr. Murr regularly advises pharmaceutical, biotechnology, technology, and medical device and diagnostic companies in connection with significant strategic transactions, including tender offers, public and private mergers, stock and asset purchases, and licensing transactions. Noteworthy engagements have included:
Mr. Murr also has significant experience in royalty monetization transactions, representing both purchasers and sellers of royalty entitlements, including synthetic royalty financing transactions. These engagements have included representing academic institutions, corporate licensors, royalty investment funds and hedge funds in a range of royalty financing transactions and structures.
University of San Diego - 1998 Juris Doctor
University of San Diego - 1998 Master of Arts
University of Oregon - 1993 Bachelor of Arts